neoantigen-activated haploidentical T cells

Neoantigen-activated haploidentical T cells (NAHTC) are a form of adoptive cell therapy in which T cells from a healthy, partially HLA-matched (haploidentical) donor are activated and expanded ex vivo against tumor-specific neoantigens before being infused into the patient. Neoantigens are unique peptides arising from somatic mutations in cancer cells and are recognized as “non-self” by the immune system. By using donor-derived (rather than autologous) T cells, this approach aims to overcome limitations associated with dysfunctional or contaminated autologous T-cell products in heavily pretreated or immunosuppressed patients. The process involves isolating peripheral blood mononuclear cells from a related donor, stimulating them with patient-specific tumor neoantigens to activate and expand reactive cytotoxic CD8+ and helper CD4+ T-cell populations, then infusing these primed lymphocytes into the recipient. This strategy is designed to elicit potent anti-tumor responses while minimizing risks such as graft-versus-host disease compared to traditional allogeneic therapies. Early-phase clinical studies have shown promising safety and efficacy signals for relapsed or refractory peripheral T-cell lymphoma (PTCL), including durable remissions[1][3].

Other names

NAHTCneoantigen-activated haploidentical T cell therapy